Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension

Shalini M Krishnan; Yeong H Ling; Brooke M Huuskes; Dorota M Ferens; Narbada Saini; Christopher T Chan; Henry Diep; Michelle M Kett; Chrishan S Samuel; Barbara K Kemp-Harper; Avril AB Robertson; Matthew A Cooper; Karlheinz Peter; Eicke Latz; Ashley S Mansell; Christopher G Sobey; Grant R Drummond; Antony Vinh

Journal article

Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension

Shalini M Krishnan, Yeong H Ling, Brooke M Huuskes, Dorota M Ferens, Narbada Saini, Christopher T Chan, Henry Diep, Michelle M Kett, Chrishan S Samuel, Barbara K Kemp-Harper, Avril AB Robertson, Matthew A Cooper, Karlheinz Peter, Eicke Latz, Ashley S Mansell, Christopher G Sobey, Grant R Drummond, Antony Vinh

Cardiovascular Research | OXFORD UNIV PRESS | Published : 2019

DOI: 10.1093/cvr/cvy252

University of Melbourne Researchers

Karlheinz Peter Author Baker Department of Cardiometabolic Health

Grants

Awarded by National Health and Medical Research Council of Australia

Awarded by European Research Council InflammAct

Funding Acknowledgements

This work was supported by the National Health and Medical Research Council of Australia (APP1143674 to G.R.D., A.M., C.S., and A.V.; APP1062721 to G.R.D., C.S., A.M. and E.L.; APP1006017 to G.R.D.; APP1079467 to C.G.S.; APP1079492 to K.P.; and APP1041766 to C.S.S.), the European Research Council InflammAct (616777 to E.L.) and the TRR57 grant by the Deutsche Forschungsgemeinschaft (to E.L.).